Lyra Therapeutics (LYRA) Research & Development (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Research & Development of $4.4 million in Q4 2025, up 8.18% on a QoQ basis from $4.0 million in Q3 2025, and down 31.19% YoY from $6.4 million in Q4 2024.
Lyra Therapeutics (LYRA) Research & Development (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Research & Development for 7 consecutive years, with $4.4 million the latest figure, recorded in Q4 2025.
- Research & Development for Q4 2025 came in at $4.4 million, down 31.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.4 million (down 57.93% YoY), and the FY2025 annual result was $18.4 million, down 57.93% from the prior year.
- Research & Development for Q4 2025 stood at $4.4 million, up from $4.0 million in the prior quarter.
- The five-year high for Research & Development was $18.2 million in Q1 2024, with the low at $4.0 million in Q3 2025.
- A 5-year average of $8.9 million and a median of $9.0 million in 2022 frame the typical range for Research & Development.
- Across the five-year window, Research & Development soared 256.87% in 2021 and sank 73.26% in 2025, its largest moves.
- Lyra Therapeutics' Research & Development stood at $10.3 million in 2021, then dropped by 8.62% to $9.5 million in 2022, then increased by 29.79% to $12.3 million in 2023, then sank by 48.13% to $6.4 million in 2024, then tumbled by 31.19% to $4.4 million in 2025.
- The last three Research & Development figures came in at $4.4 million (Q4 2025), $4.0 million (Q3 2025), and $5.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 97.90 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 4.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.38 Mn |
| Sep 30, 2025 | 4.05 Mn |
| Jun 30, 2025 | 5.11 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Dec 31, 2024 | 6.36 Mn |
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 13.26 Mn |
| Mar 31, 2024 | 18.24 Mn |
| Dec 31, 2023 | 12.27 Mn |
| Sep 30, 2023 | 12.37 Mn |
| Jun 30, 2023 | 10.80 Mn |
| Mar 31, 2023 | 12.60 Mn |
| Dec 31, 2022 | 9.45 Mn |
| Sep 30, 2022 | 10.05 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 8.51 Mn |
| Dec 31, 2021 | 10.34 Mn |
| Sep 30, 2021 | 7.08 Mn |
| Jun 30, 2021 | 7.51 Mn |
| Mar 31, 2021 | 4.77 Mn |